Guide · Updated November 2026

What Is Orforglipron (Foundayo)? Lilly’s Oral GLP-1 Pill

Orforglipron, sold as Foundayo, is Eli Lilly's once-daily oral GLP-1 pill. Lilly announced FDA approval on April 1, 2026, for chronic weight management, with shipping from LillyDirect starting April 6, per Lilly's announcement. Unlike the oral semaglutide pills (Rybelsus and the Wegovy pill), Foundayo can be taken with or without food. Here is what it is, how the dosing works, what the trials showed, and what it costs. Checked against the FDA label and LillyDirect on November 4, 2026.

Quick Facts

How Orforglipron Is Different From Other GLP-1s

Every other GLP-1 medication on the market, including Ozempic, Wegovy, Mounjaro, and Zepbound, is a peptide. Peptides get broken down in the gut, which is why most of them are injections, and why the oral semaglutide pills (Rybelsus for diabetes and the Wegovy pill for weight) have to be taken in the morning on an empty stomach with no more than 4 ounces of water, followed by a 30-minute wait before eating or taking other medication.

Orforglipron is not a peptide. It is a small molecule, chemically closer to an everyday pill than to insulin or semaglutide, and the label says to take it once daily with or without food. That is the pitch: GLP-1 receptor activation without an injection and without the timing rules of oral semaglutide. Our oral vs. injectable GLP-1 guide compares Foundayo against Rybelsus and the higher-dose oral Wegovy pill in more detail.

I have been on injectable Mounjaro since 2024 and track my results with DEXA scans, so I get asked a lot whether a pill like this makes the injection obsolete. My honest read after going through the trial data: not yet, not at this efficacy gap. It is a real option for people who were never going to start an injectable in the first place, which is a large group, but it is not currently a like-for-like swap for someone already doing well on tirzepatide or semaglutide.

Dosing Schedule

The Foundayo label starts everyone at 0.8 mg, then 2.5 mg, then 5.5 mg, each for at least 30 days. After that, the dose may be raised to 9 mg, 14.5 mg, or 17.2 mg, again after at least 30 days at the current dose, based on how you respond and tolerate it:

At the minimum pace, reaching the 17.2 mg maximum takes about five months. Steps above 5.5 mg are optional under the label and depend on your response and tolerability, so not everyone climbs to the top. Your prescriber sets the pace.

Two interaction details from the label. First, if you take a strong CYP3A4 inhibitor (a group that includes some antifungals and antibiotics), the maximum Foundayo dose is 9 mg once daily, and some of these drugs should be avoided altogether. Strong CYP3A4 inducers should also be avoided because they can make Foundayo less effective. Second, if you use birth control pills, the label advises switching to a non-oral method or adding a barrier method for 30 days after starting Foundayo and for 30 days after each dose increase. The label also says to stop Foundayo if you become pregnant. If you take other prescription medications, ask your prescriber or pharmacist rather than self-assessing.

What the Trials Actually Showed

The headline number in Lilly’s approval announcement is 12.4% weight loss (27.3 lbs) at 72 weeks at the highest dose in the ATTAIN-1 trial, a placebo-controlled Phase 3 study of 3,127 adults with obesity or overweight without diabetes. That figure counts people who stayed on treatment.

The same announcement and the FDA label also give the figure for everyone who was randomized, whether or not they kept taking the drug: 11.1% weight loss at the 17.2 mg dose over 72 weeks, against 2.1% for placebo. Lower doses showed a clear dose-response pattern: 8.3% at 9 mg and 7.4% at 5.5 mg. The label notes that the trials used an investigational formulation, with results shown as equivalent tablet doses. The 11.1% figure is the more conservative one to plan around. The pound figures below are our conversion of the label’s percentages and baseline weights.

For comparison, injectable tirzepatide (Mounjaro/Zepbound) produced 20.9% weight loss at its top dose in the SURMOUNT-1 trial, and injectable semaglutide (Wegovy) produced 14.9% in STEP 1. These are separate trials, so the comparison is rough. Orforglipron’s results are meaningful but currently trail both injectables. A pill with somewhat lower average weight loss is still the right trade-off for some people, particularly anyone who was avoiding GLP-1 treatment specifically because of needle aversion or the oral semaglutide food and water rules.

Side Effects and the Boxed Warning

Foundayo carries the same class-wide boxed warning as every other approved GLP-1: a warning about thyroid C-cell tumors, based on findings in rodent studies of medicines that work the same way, not on evidence of the effect in humans. Notably, orforglipron itself did not produce these tumors in the rodent testing Lilly conducted, and it is not known whether the class warning applies to humans at all for any GLP-1. It is required on the label as a precaution. Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not take it, and anyone who develops a neck lump, persistent hoarseness, trouble swallowing, or shortness of breath while on it should contact their prescriber.

Gastrointestinal side effects are common and were the most frequent reason people stopped treatment. The label pools two 72-week trials:

• Nausea: 26% at 5.5 mg, 34% at 9 mg and 35% at 17.2 mg, vs 10% on placebo. Nausea, vomiting and diarrhea were more common during dose escalation and decreased over time.
• Constipation, diarrhea and vomiting: 20% to 27%, 21% to 25%, and 13% to 24% by dose, vs 9%, 11% and 4% on placebo
• Discontinuation due to side effects: 6% to 10% depending on dose vs 3% on placebo, with GI side effects driving discontinuation in 3% to 6% of patients vs 0.7% on placebo

The label also carries warnings shared with the class, including pancreatitis, gallbladder disease, and kidney injury from dehydration when vomiting or diarrhea is severe. Call your prescriber if you have severe stomach pain or cannot keep fluids down.

Reported GI rates for orforglipron run on the higher end compared with other GLP-1s, though direct comparisons across different trials are unreliable since each drug’s studies used different populations and protocols. The GI side effect pattern (worse when starting or increasing dose, easing over time) matches what people report on injectable tirzepatide and semaglutide.

Price and Where to Get It

Lilly prices Foundayo by dose tier on LillyDirect. Here is what the LillyDirect Foundayo page listed for self-pay on Nov 4, 2026:

For 14.5 mg and 17.2 mg, LillyDirect says regular prices apply if you do not refill within 45 days. For patients with eligible commercial insurance whose plan covers Foundayo, Lilly says the price can drop to as little as $25 per month, with government beneficiaries excluded. Our copay card guide covers how these cards work. LillyDirect says Foundayo is currently available by prescription through LillyDirect, with home delivery or free pickup at a retail pharmacy, and lists Amazon Pharmacy and Walmart Pharmacy among its dispensing partners. Confirm current pricing on LillyDirect before ordering.

Is It Approved for Type 2 Diabetes?

Not as a diabetes treatment, based on the July 2026 label. The approval covers weight reduction and maintenance. One of the two trials behind it (Trial 2) enrolled 1,613 adults with type 2 diabetes and overweight or obesity. In that 72-week trial, weight loss was 5.1% at 5.5 mg, 7% at 9 mg and 9.6% at 17.2 mg, vs 2.5% on placebo. So people with diabetes can be prescribed it for weight, but using it specifically to manage blood sugar would be off-label. If you take insulin or a sulfonylurea, the label warns of a higher risk of low blood sugar, so your prescriber may adjust those drugs.

FAQ

Is Foundayo the same as Ozempic or Wegovy?

No. They are all GLP-1 receptor agonists, but Ozempic and Wegovy contain semaglutide, a peptide. Foundayo contains orforglipron, a non-peptide small molecule. They work on the same receptor but are chemically different drugs with different dosing, different side effect rates, and different trial results.

Does Foundayo need to be taken on an empty stomach?

No. This is the main practical difference from oral semaglutide (Rybelsus and the Wegovy pill), which must be taken in the morning on an empty stomach with minimal water and a 30-minute wait before eating. The Foundayo label says to take it once daily, with or without food.

How does Foundayo compare to Mounjaro or Zepbound for weight loss?

Injectable tirzepatide (Mounjaro/Zepbound) produced more weight loss in its own trials, 20.9% at the top dose in SURMOUNT-1 versus 11.1% for Foundayo’s top dose in ATTAIN-1. These were separate trials, not a head-to-head. Foundayo trades some efficacy for the convenience of a pill and no injection.

Is Foundayo covered by insurance?

Coverage varies by plan. Lilly’s savings card can bring the price to as little as $25 per month for people with eligible commercial insurance whose plan covers Foundayo. For Medicare, Foundayo is one of the drugs covered by the Medicare GLP-1 Bridge, with a $50 monthly copay for people who meet its criteria. Check your specific formulary rather than assuming coverage either way.

Will there be an oral tirzepatide pill like Foundayo?

Foundayo is built on orforglipron, a different molecule from tirzepatide (Mounjaro/Zepbound). We did not find an oral tirzepatide product on LillyDirect as of Nov 4, 2026. Any future oral version would need its own FDA approval.

This guide summarizes publicly reported trial data, FDA approval information, and manufacturer pricing for general information only. It is not medical advice and does not recommend Foundayo or any other medication for any individual. Whether a GLP-1 medication is appropriate, and at what dose, is a decision between a patient and a licensed prescriber. Full details in our disclaimer.

Related

Guides:

• Oral vs Injectable GLP-1
• GLP-1 vs. Bariatric Surgery
• GLP-1 Copay Cards and Patient Assistance Programs
• Tirzepatide Dosage Chart: mg to Units

Medications: Mounjaro · Wegovy · Compounded Tirzepatide

Compare: All Providers · Best GLP-1 Programs · All Guides

What we checked

This AI-assisted public-source desk check reviewed the Foundayo prescribing information (revised July 2026), Lilly’s April 2026 approval announcement, the LillyDirect Foundayo page, Medicare.gov’s GLP-1 Bridge page, and the SURMOUNT-1 and STEP 1 publications on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.